Argenx NV, of Breda, the Netherlands, said it priced its IPO selling 5.86 million American depository shares (ADSs) at $17 each for anticipated gross proceeds of about $100 million. The underwriters have been granted a 30-day option to purchase up to an additional 879,750 ADSs. The ADSs began trading on Nasdaq Thursday under the symbol ARGX and closed at $23.

Repros Therapeutics Inc., of The Woodlands, Texas, said it plans to sell 2.74 million shares of common stock and pre-funded series C warrants to purchase 2.24 million shares of common stock. Also included in the offering are series A warrants to purchase 3.74 million shares of common stock and series B warrants to purchase 2.49 million shares of common stock. The gross proceeds are expected to be approximately $3 million. Laidlaw & Co. (UK) Ltd. is the sole book-running manager for the offering. Shares of Repros (NASDAQ:RPRX) fell 28 cents, or 35 percent, to close Thursday at 52 cents.

RM Global, of Tel Aviv, Israel, launched the RMGP Biopharma Fund to invest in the Futurx portfolio, an Israel-based, early stage incubator founded by New Brunswick, N.J.-based Johnson & Johnson, Takeda Ventures and Orbimed. The fund, which completed its first closing of $30 million and plans to open to new investors for second closings in the near future, is supporting work in areas such as immuno-oncology, nervous system diseases and orphan diseases.

Verona Pharma plc, of London, said it closed the underwriters' exercise of the overallotment option to purchase additional American depositary shares (ADS) in connection with the firm's offering of new ordinary shares, comprising ADSs and ordinary shares. Underwriters purchased an additional 692,385 ADSs, representing about 5.5 million ordinary shares, at a price of $13.50 per ADS, for additional aggregate proceeds of about $9.3 million and total aggregate proceeds of about $89.3 million. Jefferies and Stifel acted as joint book-running managers. Wedbush Pacgrow and Suntrust Robinson Humphrey acted as co-managers.

Xeris Pharmaceuticals Inc., of Chicago, said it closed a $30 million series C financing led by Redmile Group together with current investors including Deerfield Management Co., Palmetto Partners, Wild Basin Investments and Asahi-Kasei Corp. New investors in the financing included Bay City Capital, Merieux Développement and members of Xeris management. The proceeds will be used to advance the phase III development and NDA submission of the company's liquid stable, prefilled, single-use, glucagon auto-injector for the treatment of severe hypoglycemia in patients with type 1 diabetes. In addition, Xeris said it will advance three programs for its ready-to-use glucagon formulation in certain chronic disease states that have unmet medical needs.

Xontogeny LLC, of Boston, said it closed a $15 million tranche of a $25 million series A financing round. The accelerator operating company was founded by Chris Garabedian, who was most recently president and CEO of Sarepta Therapeutics Inc. He will serve as chairman and CEO. The company plans to use the financing to manage operations, build a team of experts and advance early stage development of life science products in its portfolio companies that will be focused across a number of serious disease areas from preclinical through clinical proof-of-concept studies.